ORIC Pharmaceuticals, Inc. (ORIC)

NASDAQ: ORIC · Real-Time Price · USD

10.80

+0.20 (1.84%)

Sep 4, 2025, 4:00 PM - Market closed

ORIC Pharmaceuticals Employees

ORIC Pharmaceuticals had 115 employees as of December 31, 2024. The number of employees increased by 15 or 15.00% compared to the previous year.

Employees

115

Change (1Y)

15

Growth (1Y)

15.00%

Revenue / Employee

n/a

Profits / Employee

-$1,193,470

Market Cap

1.05B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	115	15	15.00%
Dec 31, 2023	100	14	16.28%
Dec 31, 2022	86	8	10.26%
Dec 31, 2021	78	17	27.87%
Dec 31, 2020	61	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

ORIC News

1 day ago - ORIC Pharmaceuticals, Inc. (ORIC) Pharmaceuticals, Inc. Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
8 days ago - ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
17 days ago - ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer - GlobeNewsWire
23 days ago - ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates - GlobeNewsWire
4 weeks ago - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
3 months ago - ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital - Benzinga
3 months ago - ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing - GlobeNewsWire
3 months ago - ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC - GlobeNewsWire